GlassScriptPhysician profile
Emily Campbell
NPI 1508091034
$1,967.58
in general payments reported to CMS, 2019-2025
36 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $233 · 2021: $599 · 2022: $166 · 2023: $245 · 2024: $253 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.85 | 2020-2025 | Ubrelvy |
| Novo Nordisk INC | $315.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $235.96 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boston Scientific Corporation | $84.44 | 2024-2025 | General - Erectile Dysfunction |
| Astellas Pharma US INC | $80.43 | 2019-2021 | |
| Allergan, INC. | $71.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $66.77 | 2021-2023 | |
| Pfizer INC. | $58.39 | 2020-2023 | |
| Horizon Therapeutics Plc | $53.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.27 | 2021-2022 | |
| Linvatec Corporation | $40.30 | 2023-2024 | Biobrace 23mm, Allograft Tissue |
| Janssen Pharmaceuticals, INC | $35.70 | 2019-2022 | |
| Pacira Therapeutics, INC. | $29.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.40 | 2019-2022 | |
| Lilly USA, LLC | $26.14 | 2021-2024 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.80 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $24.50 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.80 | 2022 | |
| Dexcom, INC. | $22.88 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $21.15 | 2019 | |
| Tactile Systems Technology INC | $19.72 | 2023 | Flexitouch Plus, Entre Plus |
| Philips North America LLC | $19.67 | 2024 | (Ck7) Extended Holter |
| Sumitomo Pharma America, INC. | $18.30 | 2023 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $18.21 | 2019 | |
| Lundbeck LLC | $17.26 | 2021 | |
| Daiichi Sankyo INC. | $16.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.92 | 2024 | Eliquis |
| Nestle Healthcare Nutrition INC. | $15.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2021 | |
| Convatec INC. | $14.60 | 2021 | |
| Cipher Pharmaceuticals US LLC | $14.24 | 2025 | Spinosad, Natroba |
| Axsome Therapeutics, INC. | $14.07 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.36 | 2021 | |
| Esperion Therapeutics, INC. | $12.93 | 2021 | |
| Depuy Synthes Sales INC. | $11.49 | 2019 | |
| Bausch Health US, LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.